Genomics England has completed installation of an enterprise imaging system that will help to support a world-pioneering initiative for cancer research. The programme is linking whole genome sequencing, pathology and radiology data, in what has been described as the world’s largest multimodal cancer research platform.

Qure.ai, one of world's leading providers of AI for healthcare, will launch its artificial intelligence (AI) playbook for radiology at this year's European Congress of Radiology. Developed with its European research partners Professor Dirk Pickuth and Dr Susanne Ohlmann-Knafo of CaritasKlinikum Saarbrücken/Germany, the playbook will provide European clinicians and radiologists with a helpful guide to understanding the business case for AI in radiology.

One of England's integrated care systems proved the benefit of modern, cloud-telephony during the COVID-19 pandemic, and is now working with X-on on new ideas to support GPs and patients, following a roll-out to practices. Associate director of digital & technology Alicia Dunsby explains.

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

A new Artificial Intelligence (AI) innovation to help speed up MRI scanning planning time and alleviate pressure on radiology services has been launched into the UK by Canon Medical Systems. Auto Scan Assist utilises Deep Learning and Machine Learning to enhance diagnostic imaging of liver, prostate, and whole-spine examinations to achieve greater efficiencies in delivering patient services.

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance Bayer’s position in digital medical imaging.

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate and scale Bayer's quantum chemistry calculations.